pyrazolanthrone has been researched along with Albuminuria in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jia, Y; Li, Y; Liu, X; Song, Y; Wang, J; Wu, H; Zhang, H; Zhou, S | 1 |
Bai, X; Geng, J; Li, X; Tian, J; Yang, F | 1 |
2 other study(ies) available for pyrazolanthrone and Albuminuria
Article | Year |
---|---|
SP600125 suppresses
Topics: Albuminuria; Animals; Anthracenes; Cell Nucleus; Diabetic Nephropathies; Fibrosis; Gene Deletion; Glucose; Inflammation; JNK Mitogen-Activated Protein Kinases; Kelch-Like ECH-Associated Protein 1; Kidney; Male; Mice, Inbred C57BL; NF-E2-Related Factor 2; Oxidative Stress; Protein Transport; RNA, Small Interfering | 2018 |
VEGF-A inhibition ameliorates podocyte apoptosis via repression of activating protein 1 in diabetes.
Topics: Albuminuria; Angiogenesis Inhibitors; Animals; Anthracenes; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; HEK293 Cells; Humans; Kidney; Podocytes; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats, Sprague-Dawley; RNA, Small Interfering; Streptozocin; Transcription Factor AP-1; Transfection; Vascular Endothelial Growth Factor A | 2014 |